Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 5;3(2):2055217317702933.
doi: 10.1177/2055217317702933. eCollection 2017 Apr-Jun.

Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate

C Chaves, R Ganguly, C Ceresia, A Camac  1
Affiliations

Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate

C Chaves et al. Mult Scler J Exp Transl Clin. .

Abstract

Background: Recent data suggest that lymphopenia is more prevalent than reported in relapsing-remitting multiple sclerosis (RRMS) patients taking dimethyl fumarate (DMF).

Objective: The objective of this study was to investigate the effect of DMF on lymphocyte subtypes in RRMS patients with and without lymphopenia.

Method: A retrospective study compared lymphocyte subtypes in DMF-treated RRMS patients with low (G1, n = 35) and normal lymphocyte counts (G2, n = 24).

Results: Fifty-nine patients were identified, with mean age 49, 71.2% females, and average DMF duration 20 months. Age, sex, baseline white blood count, disease and treatment durations were similar between groups. Prior interferon therapy and baseline lower normal lymphocyte counts were more frequent in G1. Mean lymphocyte counts were 0.8 ± 0.2 × 109/L in G1 and 1.6 ± 0.3 × 109/L in G2. CD3+, CD4+, and CD8+ T cell mean counts were lower (p < 0.0001), while CD4/CD8 ratio higher (p = 0.03) in G1 than G2. Mean CD19 + B cell counts were normal; however, values were lower in G1 (p = 0.04). After adjusting for confounders, significantly positive correlations were noted between lymphocyte counts and CD3 + , CD4+, CD8+ T, and B cell counts. Negative correlation was observed between lymphocyte counts and CD4/CD8 ratio driven by low CD8+ T cell counts.

Conclusion: DMF treatment predominantly impacts T cells, in particular CD8+ subtype. This finding may have implications in this population's immunocompetence.

Keywords: Dimethyl fumarate; immunology; multiple sclerosis.

PubMed Disclaimer

References

    1. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107. - PubMed
    1. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097. - PubMed
    1. Longbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Mult Scler J 2015; 21: 796–797. - PMC - PubMed
    1. Longbrake EE, Naismith RT, Parks BJ, et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin 2015; 1: 1–8. - PMC - PubMed
    1. Chaves C, Dionne C, Ganguly R, et al. Safety and efficacy of dimethyl fumarate in patients with multiple sclerosis – real world experience. Neurology 2015; 84(14 Supplp3.241.